The first participant has been dosed in an investigator-led Phase 2 trial testing pegsebrenatide as a potential treatment for ...

Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on ...

Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish ...

"In 2020 — after three years of immunosuppression — when I learned of mRNA vaccine research for MS, I was relieved," writes ...

In a budget dominated by cost-of-living pressures and global instability, the Federal Government has unveiled a major ...

Compared to routine care, stem cell-enriched autologous lipotransfer produces significantly greater improvement in orofacial ...

Growing at a rapid pace, Apex Eyecare is poised to hire a second optometrist and a nurse practitioner in the coming months, ...

Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected ...

Misshapen proteins cause a mess of trouble—particularly in neurodegenerative diseases. But a new study suggests it's possible ...

Iowa Attorney General Brenna Bird secured a major legal victory against a group of "con artists" accused of preying on vulnerable Iowans through a sophisticated predatory marketing ...

Neurizon gains ethics approval for NUZ-001 oral liquid Phase 1 ALS study in Australia; trial slated to start Q3 2026 and ...

A new type of MRI scan may distinguish active from chronic MS lesions without the need for injected contrast dye.